ACER

ESMA finds natural gas futures markets functioned appropriately during the August 2022 price surge

Retrieved on: 
Thursday, November 9, 2023
Agency, Falls, May, March, ACER, European Securities and Markets Authority, Contract, ESMA, Time, CCP, Electricity, Annual report, Uncertainty, Natural gas, Cryptocurrency, EU

ESMA finds natural gas futures markets functioned appropriately during the August 2022 price surge

Key Points: 
  • ESMA finds natural gas futures markets functioned appropriately during the August 2022 price surge
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, today publishes a study on the record surge in prices in European natural gas futures markets in August 2022.
  • Natural gas derivative markets came into the spotlight with the Russian invasion of Ukraine, which drove uncertainty and later led to falls in Russian supplies.
  • Despite the record prices during August 2022, the findings presented in the study do not show correspondingly high illiquidity.
  • Taken together, these elements suggest that markets continued to function appropriately during the August 2022 market events.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals

Retrieved on: 
Thursday, November 2, 2023
Glass Lewis, Sale, Security (finance), OTC Markets Group, Form, Acquisition, NOT, Proxy, Prospectus, Glass, Bankruptcy, Special, ACER, Annual report, Therapy, Failure, ISS, CVR, Calendar, Communication, Holding company, Airline, Zebra, Acer

ISS and Glass Lewis are widely recognized as the leading independent voting and corporate governance advisory firms.

Key Points: 
  • ISS and Glass Lewis are widely recognized as the leading independent voting and corporate governance advisory firms.
  • Commenting on the proxy advisors’ reports, Chris Schelling, CEO and Founder of Acer, said: "The ISS and Glass Lewis recommendations are consistent with our view that the merger with Zevra is in the best interest of Acer shareholders."
  • Failure to vote or an abstention from voting will have the same effect as a vote "AGAINST" the merger proposal.
  • Acer shareholders are urged to read these materials because they contain important information about Acer, Zevra and the proposed merger.

ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER

Retrieved on: 
Tuesday, October 10, 2023
Legal, Professional Services, ACER, KSF, Therapy, Contingent value rights, Sale, Zebra, Acer

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA).
  • Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AGE, NEWR, CCF, ACER

Retrieved on: 
Monday, September 18, 2023
New Relic, AGE, KKR, Empire, Sale, CCF, CVR, Francisco Partners, AgeX Therapeutics, Monteverde, Acer, ACER, Therapy, NYSE, Security (finance), Zebra

Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.

Key Points: 
  • Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, CCF shareholders are expected to receive $127.50 in cash per share they own.
  • Acer Therapeutics, Inc. (Nasdaq: ACER ), relating to its proposed merger with Zevra Therapeutics, Inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – VRTV, HCCI, RETA, ACER

Retrieved on: 
Tuesday, September 12, 2023
Reata Pharmaceuticals, Empire, Sale, Biogen, CVR, Monteverde, Acer, ACER, Therapy, HCCI, NYSE, Dubilier, Security (finance), Zebra

Under the terms of the agreement, VRTV shareholders will receive $170.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, VRTV shareholders will receive $170.00 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, HCCI shareholders are expected to receive $45.50 in cash per share they own.
  • Acer Therapeutics, Inc. (Nasdaq: ACER ), relating to its proposed merger with Zevra Therapeutics, Inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AGE, ESTE, ACER, CPRI

Retrieved on: 
Wednesday, September 6, 2023
Permian, CPRI, Tapestry, AGE, Empire, Sale, Capri Holdings, CVR Partners, AgeX Therapeutics, Monteverde, TXO Production Corp. v. Alliance Resources Corp., Acer, ACER, Therapy, NYSE, Security (finance), Zebra

Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.

Key Points: 
  • Under the terms of the agreement, AGE shareholders are expected to own approximately 25% of the combined company.
  • Earthstone Energy, Inc. (NYSE: ESTE ), relating to its proposed merger with Permian Resources Corp.
  • Under the terms of the agreement, ESTE shareholders will receive 1.446 shares of Permian per share they own.
  • Under the terms of the agreement, CPRI shareholders will receive $27.05 in cash per share they own.

ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER

Retrieved on: 
Tuesday, September 5, 2023
Class Action Lawsuit, Professional Services, Legal, Sale, KSF, ACER, Therapy, Contingent value rights, Zebra, Acer

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA).
  • Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Lifshitz Law PLLC Announces Investigations of RPT, HT, SMMF, and ACER

Retrieved on: 
Sunday, September 3, 2023
HT, Telephone, PLLC, Kimco Realty, Sale, Advertising, ACER, RPT, Therapy, Contingent value rights, KSL Capital Partners, Hewlett, Financial adviser, Online shopping, Security (finance)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HT to KSL Capital Partners, LLC for $10.00 per share in cash for each share of HT common stock owned.

Key Points: 
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HT to KSL Capital Partners, LLC for $10.00 per share in cash for each share of HT common stock owned.
  • Lifshitz L aw PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of SMMF and Burke & Herbert Financial Services Corporation.
  • Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ACER to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra Therapeutics, Inc. for each share of ACER common stock owned.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, August 31, 2023
Class Action Lawsuit, Other Professional Services, Legal, Professional Services, Zebra, Sale, ACER, Fraud, Therapy, Advertising, Contingent value rights, Security (finance), Acer

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra’s common stock for each share of Acer’s common stock is fair to Acer shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra’s common stock for each share of Acer’s common stock is fair to Acer shareholders.
  • On behalf of Acer shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Retrieved on: 
Thursday, August 31, 2023
LLP, Business development, Relief Therapeutics, Contingent value rights, NOL, William Blair & Company, UCD, Business, Pillsbury Winthrop Shaw Pittman, Emetine, UCD GAA, Acquisition, VWAP, Patient, Niemann–Pick disease, Physician, CVR College of Engineering, Webcast, ACER, NPC, Rare, FDA, Therapy, Pharmaceutical industry, Security (finance), Financial adviser, Zebra, Acer

Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.

Key Points: 
  • Zevra has also purchased Acer’s secured debt at a discount from Nantahala Capital (Nantahala) through a series of transactions in capital efficient structure.
  • In addition, Zevra has agreed to provide Acer with a bridge loan facility for up to $16.5 million, subject to certain terms and conditions.
  • The merger is expected to expand Zevra's rare disease portfolio, as well as increase and diversify its revenues with the addition of a U.S. commercial asset, OLPRUVA, indicated for the treatment of UCDs.
  • Pillsbury Winthrop Shaw Pittman LLP served as legal advisor to Acer, and William Blair & Company, LLC served as exclusive financial advisor to Acer.